Literature DB >> 6525333

Synthesis and characterization of a set of four dodecadeoxyribonucleoside undecaphosphates containing O6-methylguanine opposite adenine, cytosine, guanine, and thymine.

B L Gaffney, L A Marky, R A Jones.   

Abstract

A set of four self-complementary dodecanucleoside undecaphosphates, d[CGNGAATTC(O6Me)GCG], where N = A, C, G, or T, has been synthesized by a phosphoramidite procedure. A single large-scale preparation of the nonamer d[DMT-GpApApTpTpCp(O6Me)GpCpG] was divided into four portions for synthesis of the dodecamers. The synthesis, purification (high-performance liquid chromatography), and characterization of each of these molecules are described. Each sequence forms a stable duplex, with a Tm between 19 and 26 degrees C lower than the Tm of the "parent" molecule d-(CGCGAATTCGCG). The lowest melting sequence is the N = T molecule; the overall order is N = C greater than A greater than G greater than T. Thus O6-methylation of guanine creates a region of localized instability in DNA regardless of the base opposite the lesion. This instability, which could disrupt some regulatory process or event, may be as significant as or more significant than is the mutation itself to the oncogenic process initiated by alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6525333     DOI: 10.1021/bi00319a004

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  High-resolution structure of a mutagenic lesion in DNA.

Authors:  G A Leonard; J Thomson; W P Watson; T Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Alkyl phosphotriester modified oligodeoxyribonucleotides. V. Synthesis and absolute configuration of Rp and Sp diastereomers of an ethyl phosphotriester (Et) modified EcoRI recognition sequence, d[GGAA(Et)TTCC]. A synthetic approach to regio- and stereospecific ethylation-interference studies.

Authors:  K A Gallo; K L Shao; L R Phillips; J B Regan; M Koziolkiewicz; B Uznanski; W J Stec; G Zon
Journal:  Nucleic Acids Res       Date:  1986-09-25       Impact factor: 16.971

3.  The synthesis of oligoribonucleotides containing O6-methylguanosine: the role of conserved guanosine residues in hammerhead ribozyme cleavage.

Authors:  J A Grasby; P Jonathan; G Butler; M J Gait
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

4.  Alkyl phosphotriester modified oligodeoxyribonucleotides. VI. NMR and UV spectroscopic studies of ethyl phosphotriester (Et) modified Rp-Rp and Sp-Sp duplexes, (d[GGAA(Et)TTCC])2.

Authors:  M F Summers; C Powell; W Egan; R A Byrd; W D Wilson; G Zon
Journal:  Nucleic Acids Res       Date:  1986-09-25       Impact factor: 16.971

5.  Mechanisms of Insertion of dCTP and dTTP Opposite the DNA Lesion O6-Methyl-2'-deoxyguanosine by Human DNA Polymerase η.

Authors:  Amitraj Patra; Qianqian Zhang; F Peter Guengerich; Martin Egli
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

6.  Base composition analysis of oligonucleotides containing apurinic sites.

Authors:  R L Morgan; J E Celebuski; J R Fino
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

7.  Protonated base pairs explain the ambiguous pairing properties of O6-methylguanine.

Authors:  L D Williams; B R Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Guanine modification during chemical DNA synthesis.

Authors:  J S Eadie; D S Davidson
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

9.  Structural studies of O6-methyldeoxyguanosine and related compounds: a promutagenic DNA lesion by methylating carcinogens.

Authors:  Y Yamagata; K Kohda; K Tomita
Journal:  Nucleic Acids Res       Date:  1988-10-11       Impact factor: 16.971

10.  Characterization of labeled oligonucleotides using enzymatic digestion and tandem mass spectrometry.

Authors:  H Wu; R L Morgan; H Aboleneen
Journal:  J Am Soc Mass Spectrom       Date:  1998-07       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.